Trials / Completed
CompletedNCT00821574
Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome
Project to Promote the Evaluation of the Cardiovascular Risk in the Clinical Practice and to Evaluate Its Evolution Following the Implementation of a Preventive Multifactorial Strategy Aimed to Reduce the Total Risk Level (SCORE Algorithm), in Subjects Suffering From Metabolic Syndrome and With a Risk Level ≥5%
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 144 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluvastatin | Fluvastatin: daily 80 mg, oral |
| DRUG | Valsartan | Valsartan: daily 160 mg, oral |
| DRUG | Hydrochlorothiazide | Hydrochlorothiazide: daily 12.5mg, oral |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2007-03-01
- Completion
- 2007-03-01
- First posted
- 2009-01-13
- Last updated
- 2017-03-01
Source: ClinicalTrials.gov record NCT00821574. Inclusion in this directory is not an endorsement.